Experimental lung disease drug may slow aging in record time

Six independent protein-based “aging clocks” all moved younger after 12 weeks on an AI-designed lung drug — in real patients.

Story Highlights

Insilico Medicine reported rentosertib shifted biological-age biomarkers in a Phase IIa study.
All six proteomic aging clocks showed younger predicted age in treated idiopathic pulmonary fibrosis patients.
The same trial reported safety and dose-linked lung function gains as its core outcome.
Proteomic clocks track risks like mortality and disease in large cohorts, adding weight to the signal.

AI-designed lung drug shows a unified biomarker shift toward youth

Insilico Medicine said its idiopathic pulmonary fibrosis drug, rentosertib (also known as ISM001-055), lowered predicted biological age across six separate proteomic aging clocks in a 12-week Phase IIa clinical study. Company researchers analyzed blood proteins over time and ran them through recognized models, including ProtAge, OrganAge, and proteomic aging clock, and reported a consistent move toward a younger profile among treated patients. The result is notable because different teams built these clocks, yet they pointed in the same direction in this dataset.

Idiopathic pulmonary fibrosis is a severe lung disease that scars tissue and robs people of breath. The rentosertib trial focused on safety and lung function first, not aging. Insilico reported the drug was well tolerated, meeting the primary endpoint. The company also described a dose-dependent improvement in forced vital capacity, a key measure of how much air a person can exhale after a full inhale. Those core pulmonary results frame the aging-clock signals as an added finding, not the study’s main goal.

What biological-age clocks measure, and why they matter

Proteomic aging clocks infer biological age by reading patterns across hundreds of blood proteins. They are trained on large cohorts to predict age and health outcomes. Multiple recent studies show these clocks track meaningful risks, including death and major diseases, across diverse populations. That record helps explain why a consistent “younger” shift across six models grabs attention. When different tools all say the same thing on the same blood, the signal deserves a closer look, even in a small trial.

Researchers used Olink proteomics, which captures a wide panel of proteins from a small sample. The six clocks included both general and organ-focused models. Agreement across them can reduce the chance that one quirky model drove the finding. Still, proteomic clocks reflect body-wide processes, and disease activity can influence them. That is why scientists treat these readouts as biomarkers linked to risk, not as proof you added years to life or reversed aging outright.

What happened in the clinic, and what comes next

Forty-plus patients with idiopathic pulmonary fibrosis took rentosertib for 12 weeks, with blood draws over time for proteomic analysis, according to Insilico’s release. The company highlighted safety across dose groups and noted signals of lung benefit. Then, in a prespecified analysis, it applied six independent aging models to the proteomic data. Each model reported a drop in predicted biological age during treatment, which the company framed as a potential aging impact that warrants further study.

Biomarkers move much faster than hard outcomes like survival. That speed is the point. If a drug shifts validated risk markers in weeks or months, it can guide investment and trial design. The most conservative read is that rentosertib changed protein patterns in a way that aging science links to lower risk. The responsible next step is a larger, longer trial that tracks function, quality of life, and clinical events alongside the same proteomic panels.

Guardrails for “anti-aging” claims

Headlines love the phrase “slows aging.” Readers deserve straight talk. The study showed a shift in biological-age biomarkers, not a proven increase in lifespan. That still matters. In population studies, higher proteomic biological age links to higher mortality and more disease. Moving in the other direction should be good news if it holds up. The cleanest takeaway is cautious and constructive: the drug changed risk-linked biology in the right direction and did so across many models.

Experimental lung disease drug may slow aging by 3-4 years, study suggests | Fox News https://t.co/sf8YpC2wUl

— G Michael Brown (@GMichaelBrown) September 9, 2026

Policy and culture should reward this kind of stepwise evidence. Patients want real options, not hype. Regulators and payers want endpoints that predict who lives longer and better. Proteomic clocks are emerging as practical tools that compress time and cost in drug development, while staying anchored to outcomes that count. If future trials confirm these findings, rentosertib could help people breathe easier today and age better tomorrow — the kind of progress worth funding and finishing.